

## RECTAL DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON  
 ROOM: ROSSETTI  
 SATURDAY APRIL 28TH, 2018, 9:00 AM – 10:15AM

CO-CHAIRS : DR. HAGEN KENNECKE & DR. REBECCA AUER  
 SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

### **CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

### **Learning Objectives:**

- To interpret and address, through clinical and translational research, the disease burden associated with malignancies of the rectum in Canada.
- To summarize recent developments in the understanding of therapeutics as these relate to malignancies of the rectum.
- To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to malignancies of the rectum.
- To interpret and apply new clinical trial methodologies in the field of clinical research in malignancies of the rectum.

### **9:00 am Setting Strategic Plan**

#### **Active/Recently Closed Trials for Update**

- |                                       |  |  |
|---------------------------------------|--|--|
| <b>9:20 am</b>                        | <b>CRC.7 (NCCTG N1048- PROSPECT):</b> A Phase II/III Trial of Neoadjuvant Folfox, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision | <b>Dr. R. Auer</b>                         |
| <b>9:25 am</b>                        | <b>CO.28:</b> Phase II: Non-Operative Management Of cT1-3 N0 Low Rectal Cancer<br><b>CO.28</b> ctDNA correlatives  | <b>Dr. C. Brown</b><br><b>Dr. J. Loree</b> |
| <b>Approved Trials in Development</b> |  |  |
| <b>9:40 am</b>                        | <b>CRC.8 (EA2165):</b> A Randomized Phase II Study of Nivolumab after Combined Modality Therapy (CMT) in High Risk Anal Cancer<br><br><b>NRG TNT:</b> Opportunity for Study Arm Proposal   | <b>Dr. R. Auer</b>                         |
| <b>9:55 am</b>                        | <b>Intergroup Task Force Update and NOM Concepts in Development</b>  | <b>Dr. R. Auer</b>                         |
| <b>10:15 am</b>                       | <b>Meeting Adjourned</b>   |  |